Gilead Sciences CEO O’Day sells $17.3 million in stock

robot
Abstract generation in progress

Gilead Sciences CEO Daniel Patrick O’Day sold 115,640 shares of common stock for $17.3 million after exercising options. The transaction was pre-arranged under a Rule 10b5-1 trading plan. This news comes amidst positive analyst sentiment for Gilead, driven by FDA approval for Yescarta in certain lymphoma cases and strong performance in its HIV pipeline, including the drug Yeztugo.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
0/400
No comments
  • Pin

Trade Crypto Anywhere Anytime
qrCode
Scan to download Gate App
Community
  • 简体中文
  • English
  • Tiếng Việt
  • 繁體中文
  • Español
  • Русский
  • Français (Afrique)
  • Português (Portugal)
  • Bahasa Indonesia
  • 日本語
  • بالعربية
  • Українська
  • Português (Brasil)